TITLE

Recombinant Erythropoietin in Humans Has a Prolonged Effect on Circulating Erythropoietin Isoform Distribution

AUTHOR(S)
Aachmann-Andersen, Niels Jacob; Just Christensen, Søren; Lisbjerg, Kristian; Oturai, Peter; Meinild-Lundby, Anne-Kristine; Holstein-Rathlou, Niels-Henrik; Lundby, Carsten; Vidiendal Olsen, Niels
PUB. DATE
October 2014
SOURCE
PLoS ONE;Oct2014, Vol. 9 Issue 10, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The membrane-assisted isoform immunoassay (MAIIA) quantitates erythropoietin (EPO) isoforms as percentages of migrated isoforms (PMI). We evaluated the effect of recombinant human EPO (rhEPO) on the distribution of EPO isoforms in plasma in a randomized, placebo-controlled, double-blinded, cross-over study. 16 healthy subjects received either low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13); high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13); or placebo on all days. PMI on days 4, 11 and 25 was determined by interaction of N-acetyl glucosamine with the glycosylation dependent desorption of EPO isoforms. At day 25, plasma-EPO in both rhEPO groups had returned to values not different from the placebo group. PMI with placebo, reflecting the endogenous EPO isoforms, averaged 82.5 (10.3) % (mean (SD)). High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2)% (p<0.00001) and 45.2 (7.3)% (p<0.00001). Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001). In both rhEPO groups, PMI on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (p = 0.029); low-dose Epoetin beta: 73.1 (17.8)% (p = 0.039)). In conclusion, Epoetin beta leaves a footprint in the plasma-EPO isoform pattern. MAIIA can detect changes in EPO isoform distribution up til at least three weeks after administration of Epoetin beta even though the total EPO concentration has returned to normal.
ACCESSION #
5299995

 

Related Articles

  • Recombinant Erythropoietin in Humans Has a Prolonged Effect on Circulating Erythropoietin Isoform Distribution. Aachmann-Andersen, Niels Jacob; Just Christensen, Søren; Lisbjerg, Kristian; Oturai, Peter; Meinild-Lundby, Anne-Kristine; Holstein-Rathlou, Niels-Henrik; Lundby, Carsten; Vidiendal Olsen, Niels // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    The membrane-assisted isoform immunoassay (MAIIA) quantitates erythropoietin (EPO) isoforms as percentages of migrated isoforms (PMI). We evaluated the effect of recombinant human EPO (rhEPO) on the distribution of EPO isoforms in plasma in a randomized, placebo-controlled, double-blinded,...

  • Recombinant human erythropoietin induces proliferation and Ca2+-influx in specific leukocyte subpopulations of rainbow trout (Oncorhynchus mykiss) blood and head kidney cells. Körbel, S.; Bittorf, T.; Siegl, E.; Köllner, B. // Journal of Comparative Physiology B: Biochemical, Systemic & Env;Mar2004, Vol. 174 Issue 2, p121 

    In mammals, erythropoietin regulates the development and differentiation of erythrocytes. Although hematopoietic cells of bony fish correspond in their ontogeneic development, morphology, and function to their mammalian counterparts, an erythropoietin (EPO)-like molecule has not been identified....

  • Evaluation of Functional Erythropoietin Receptor Status in Skeletal Muscle In Vivo: Acute and Prolonged Studies in Healthy Human Subjects. Christensen, Britt; Lundby, Carsten; Jessen, Niels; Nielsen, Thomas S.; Vestergaard, Poul F.; M�ller, Niels; Pilegaard, Henriette; Pedersen, Steen B.; Kopchick, John J.; J�rgensen, Jens Otto L. // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Background: Erythropoietin receptors have been identified in human skeletal muscle tissue, but downstream signal transduction has not been investigated. We therefore studied in vivo effects of systemic erythropoietin exposure in human skeletal muscle. Methodology/Principal Findings: The...

  • Homology Modeling of Turmerin and its Molecular Interaction with Human Erythropoietin. Saxena, Sandeep; Tiwari, Anshul; Srivastava, Prachi // World Journal of Retina & Vitreous;Jan-Apr2012, Vol. 2 Issue 1, p1 

    Erythropoietin, a protein, is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy. Turmerin, a protein of Curcuma longa L. Inspite of many other medicinal properties possesses antidiabetic properties too....

  • Erythropoietin: Cytoprotection in Vascular and Neuronal Cells. Z. Chong; J-Q. Kang; K. Maiese // Current Drug Targets - Cardiovascular & Haematological Disorders;Jun2003, Vol. 3 Issue 2, p141 

    One of the principal functions of erythropoietin (EPO) is to stimulate the survival, proliferation, and differentiation of immature erythroid cells. Yet, EPO has recently been shown to modulate cellular signal transduction pathways to perform multiple functions other than erythropoiesis. EPO is...

  • Working capacity is increased following recombinant human erythropoietin treatment. Mayer, Gert; Thum, Johanna; Cada, Eva Maria; Stummvoll, Hans Krister; Graf, Helmut // Kidney International;Oct1988, Vol. 34 Issue 4, p525 

    To investigate the effect of partial correction of anemia in patients maintained by chronic intermittent hemodialysis on aerobic and anaerobic working capacity, eight patients underwent a bicycle spiro-ergometry before and after treatment with recombinant human erythropoietin (r-HuEPO). The...

  • Isolation and characterization of an anti-recombinant erythropoietin single-chain antibody fragment using a phage display antibody library. Jiebo Mi; Jin Yan; Zhenquan Guo; Meiping Zhao; Wenbao Chang // Analytical & Bioanalytical Chemistry;Sep2005, Vol. 383 Issue 2, p218 

    The production of a large amount of specific antibodies against erythropoietin (EPO) is necessary for both clinical treatment and doping control. However, the weak immunogenicity of EPO and the side effects of excessive injection make the conventional immunological protocol rather inefficient...

  • Renoprotective effect of erythropoietin (EPO): Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Duk-Hee Kang; Eun-Young Park; Eun Sun Yu; Young-Suk Lee; Kyun-Il Yoon // Kidney International;May2005, Vol. 67 Issue 5, p1683 

    Examines the renoprotective effect of erythropoietin (EPO) in chronic renal failure patients. Relation of the mechanisms of the beneficial effect of EPO on patients’ survival to an increased oxygen delivery to tissues and reduction of hypoxia with anemia; Association of EPO treatment in...

  • Invited Comments. Hoke, Ahmet // Neurology India;Mar2006, Vol. 54 Issue 1, p63 

    The article focuses on the neuroprotective role of erythropoietin (EPO) in epilepsy. A study has been conducted on EPO preconditioning on hippocampus neuronal apoptosis following status epilepticus induced by Li-pilocarpine in rats. EPO and its receptor has been shown to be present in the...

  • N-Glycans Stabilize Human Erythropoietin through Hydrophobic Interactions with the Hydrophobic Protein Surface: Studies by Surface Plasmon Resonance Analysis1. Toyoda, Teruko; Arakawa, Tsutomu; Yamaguchi, Haruki // Journal of Biochemistry;2002, Vol. 131 Issue 4, p511 

    Human erythropoietin (EPO) produced in Chinese hamster ovary cells is a hydrophobic protein highly stabilized by multibranchedcomplex-type N-glycans. To reveal the molecular basis of the interaction between the N-glycans and the EPO protein, complex-type N-glycans of different structures were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics